Midwest Product Stewardship Council (MPSC) Cynthia Moore

Size: px
Start display at page:

Download "Midwest Product Stewardship Council (MPSC) Cynthia Moore"

Transcription

1 Midwest Product Stewardship Council (MPSC) Cynthia Moore Recycling Program Coordinator Recycling and Solid Waste Section Bureau of Waste & Materials Management Wisconsin Department of Natural Resources Midwest Product Stewardship Council

2 Our mission: Midwest Product Stewardship Council (MPSC) a group of government organizations that promote a common understanding and the integration of the principles of producer stewardship into the policy and economic structures of the Midwestern United States Our approach Support consistency in policy and implementation through networking and dialogue, both regionally and nationally Support establishment of state-based organizations to ensure buy-in and representation from local governments. Midwest Product Stewardship Council

3 Work Plan Priorities Support consistency in PS language and policies Support establishment of state-based groups Host scheduled calls and annual meeting networking, outside speakers, issues identification Coordinate issue specific networking calls or actions Hg lamps conference calls, pharmaceuticals Develop outreach materials templates, sample resolutions, presentations Seek funding opportunities GLRI Proposal to establish state-based pharmaceutical collection programs in GL states Midwest Product Stewardship Council

4 Our members Representatives of state and local gov t Steering Committee (at least 1 per state) Co-chairs: Cynthia Moore (WI), Leslie Wilson (MN) Garth Hickle & Peder Sandhei (MN), Theresa Steiner (IA), Becky Jayne (IL), Chris Newman (EPA 5), Chris Affeldt (MI), Jennifer Havens (WI) General Membership: over 90 registered from Midwest area states. Midwest Product Stewardship Council

5 Invited Speakers 2010 Melissa Walsh Innes, ME House of Representative. (Authored ME PS Framework legislation) Jen Holiday, Chair of the Vermont PS Council Bill Worrell, San Luis Obispo retail take back program Heidi Sanborn, ED and Rob D Arcy, Chair, CA PS Council Representatives from other State PS Councils (NW, TX, NYC) Rep from CalRecycle (formerly the CA Integrated Waste Management Board) on the CA framework bill check list Alison Keane, American Coatings Association Midwest Product Stewardship Council

6 Product Stewardship and Pharmaceu3cals Sierra Fletcher Product Stewardship Ins3tute April 20,2011

7 Clear & Consistent Message January 24,

8 Poten8al Roles in EPR: Pharmaceu8cals Manufacturers develop and implement take- back program Would choose combina3on of available mechanisms Meet program minimum requirements/goals Government oversees program & enforces against non- compliant manufacturers Educa3on & outreach Collec3on Retail pharmacies, clinics, law enforcement could serve as collec3on sites *depending on regula.ons Consumers get informa3on about what to do with leiover drugs & dispose accordingly 8

9 Post- Consumer Pharmaceu8cal Stewardship Associa8on - Canada Mandatory Programs: Bri3sh Columbia Established in 2000 more than 97.5% of all pharmacies are par3cipa3ng in the program (voluntarily) pa3ents have access to over 1080 collec3on loca3ons Manitoba Established in February

10 Companies Participating in PCPSA 1. AbboY Laboratories Limited 2. Abraxis BioScience 3. Actelion Pharmaceu3cals Canada Inc. 4. Advantage CKN 5. Afexa Life Sciences Inc. 6. Alcon Canada 7. Amgen Canada Inc. 8. Amway Canada 9. Apotex Inc. 10. Ashbury Biologicals Inc. 11. Astellas Pharma 12. AstraZeneca Canada Inc. 13. Au Naturel Inc. 14. Axcan Pharma Inc. 15. Bayer Inc. 16. Baxter Canada 17. Bioforce Canada 18. Biogen Idec Canada Inc. 19. Biovail Pharmaceu3cals Canada 20. Boehringer Ingelheim Canada Ltd. 21. Boiron 22. Bristol- Myers Squibb Pharmaceu3cal Group 23. Canada Safeway Ltd. 24. ChaYem (Canada) Inc. 25. Church & Dwight Canada 26. Cobalt Pharmaceu3cals Inc. 27. Combe Incorporated 28. Costco 29. Cytex Pharmaceu3cal Inc. 30. Eli Lilly Canada Inc. 31. EMD- Serono Canada Inc 32. Enzyma3c Therapy 33. Ferring Inc. 34. Gaia Garden Herbal Inc. 35. Galderma Ltd 36. General Nutri3on Centres Canada 37. GlaxoSmithKline Consumer Healthcare 38. GlaxoSmithKline Inc. 39. Graceway Pharmaceu3cals 40. Helix BioPharma Corp. 41. Herbalife of Canada 42. Holista Health Canada 43. Hospira Healthcare Corpora3on 44. Hudson s Bay Company 45. Indigene Pharma Inc. 46. Ins3tut Rosell 47. Jamieson Laboratories Ltd. 48. Janssen- Ortho Inc. 49. Johnson & Johnson Inc. 50. Katz Group Canada Ltd 51. King Pharmaceu3cals 52. Kripps Pharmacy 53. Laboratoire RIVA Inc. 54. Leo Pharma Inc. 55. Loblaw Companies Ltd 56. London Drugs Limited 57. Lundbeck Canada Inc. 58. Mead Johnson Nutri3onals 59. Mentholatum Co. of Canada Ltd. 60. Merck Frosst Canada & Co. 61. Mylan Canada 62. Natural Factors Nutri3onal Products Ltd. 63. Nature's Sunshine Products 64. Novar3s Consumer Health Canada Inc. 65. Novar3s Pharma Canada Inc. 66. Novo Nordisk Canada Inc 67. Novopharm Ltd. / Teva Neuroscience 68. Nu- Pharm Inc 69. Nucro- Technics Incorporated 70. Nycomed Canada Inc. 71. Odan Laboratories 72. Omega Alpha Pharmaceu3cals 73. Omega Laboratories 74. Organika Health Products Inc. 75. Overwaitea Food Group Ltd Partnership 76. Paladin Labs Inc. 77. Patheon Inc. 78. Peoples Drug Mart 79. Pfizer Canada Inc 80. Pharmasave 81. Pharmascience Inc. 82. PharmEng Technology Inc. 83. Pla3num Naturals 84. Procter & Gamble Inc. 85. Proctor & Gamble Pharmaceu3cals Canada Inc 86. ProMedics Nutraceu3cal Ltd 87. Purdue Pharma 88. Ranbaxy Pharmaceu3cals Canada Inc. 89. Ra3opharm 90. Rivex Pharma Inc. 91. Roche Canada 92. Ropack Inc. 93. Sanofi- Aven3s Canada Inc. 94. Sandoz Canada 95. Schering Canada Inc. 96. Seaford Pharmaceu3cals 97. Sepracor Pharmaceu3cals Inc. 98. Servier Canada Inc. 99. Shaklee Canada Inc Shire Canada Inc Shoppers Drug Mart, Pharmaprix 102. SISU Inc Solvay Pharma Inc S3efel Canada Inc Swiss Herbal Remedies Ltd Taro Pharmaceu3cals Inc Tianshi Health Products 108. Trophic Canada 109. UniPHARM Wholesale Drugs 110. USANA Canada Co Valeant Canada Limited 112. Vita Health Products Inc Wal- Mart Pharmacy 114. Wellspring Pharmaceu3cals 115. Westcoast Naturals 116. WN Pharmaceu3cals Ltd Wyeth Consumer Healthcare Inc Wyeth - Canada

11 Learn More about the Post- Consumer Pharmaceu8cal Stewardship Associa8on Learning from Canada: Post Consumer Pharmaceutical Stewardship Association Thursday May 5th 4-5pm Eastern / 3-4pm Central Ginette Vanasse, Post Consumer Pharmaceutical Stewardship Association Kate@productstewardship.us for more information. 11

12 EPR for Pharmaceu8cals Legisla8on in the U.S study bills in CA, VT, RI other take-back legislation in a dozen states 12

13 Yesterday: White House s Prescrip8on Drug Abuse Preven8on Plan The following ac5ons will be taken to increase proper disposal of prescrip5on drugs and prevent diversion: While the administra3ve process to establish the DEA medica3on disposal rule is underway,19 DEA and other Federal agencies shall conduct addi3onal take- back ac3vi3es Once DEA regula3ons on controlled substance prescrip3on drug disposal have been established, develop and execute a robust public educa3on ini3a3ve... Once DEA regula3ons have been established, engage PhRMA and others in the private sector to support community- based medica3on disposal programs. hyp:// April 15,

14 Contact Sierra Fletcher PSI Director of Policy & Programs

Pharmaceuticals and Product Stewardship. Sierra Fletcher Product Stewardship Institute April 29, 2011

Pharmaceuticals and Product Stewardship. Sierra Fletcher Product Stewardship Institute April 29, 2011 Pharmaceuticals and Product Stewardship Sierra Fletcher Product Stewardship Institute Who is the Product Stewardship Institute? Non profit founded in 2000 Membership 47 States 200+ Local governments 70+

More information

THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EUROPE EDITION)

THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EUROPE EDITION) THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EUROPE EDITION) Feedback from 797 patient groups in Europe PUBLISHED APRIL 2016 The perception [of pharma] has changed in the last years,

More information

Full-Disclosure Form

Full-Disclosure Form Neuroscience Education Institute Full-Disclosure Form 1930 Palomar Point Way, Ste. 101 Carlsbad, CA 92008 Tel 760-931-8857 Fax 760-931-8713 NEI requires all planners, teachers/speakers, and authors/content

More information

Online Disclosure Form Submission

Online Disclosure Form Submission Online Disclosure Form Submission Full-Disclosure Form NEI requires all planners, teachers/speakers, and authors/content developers involved with CME content to disclose all financial relationships with

More information

PROGRAM PLAN FOR THE ONTARIO SHARPS COLLECTION PROGRAM MAY 2013

PROGRAM PLAN FOR THE ONTARIO SHARPS COLLECTION PROGRAM MAY 2013 PROGRAM PLAN FOR THE ONTARIO SHARPS COLLECTION PROGRAM MAY 2013 EXECUTIVE SUMMARY Ontario Regulation 298/12 "Collection of Pharmaceuticals and Sharps - Responsibility of Producers" came into force on October

More information

Code of Conduct Interfarma Review 2012

Code of Conduct Interfarma Review 2012 Code of Conduct Interfarma Review 2012 Segundo Congreso Latinoamericano de Compliance de la Industria Farmacéutica e Insumos para la Salud, y el Foro de Buenas Prácticas Interfarma has a cooperation agreement

More information

Representing Healthcare Distribution in Canada

Representing Healthcare Distribution in Canada Representing Healthcare Distribution in Canada OUR VISION Ensuring safe, secure, and timely access to life-saving medicines and quality healthcare products for every Canadian. OUR COMMITMENT IMPLEMENTING

More information

THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (NORDIC EDITION)

THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (NORDIC EDITION) THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (NORDIC EDITION) Feedback from 147 Nordic patient groups PUBLISHED JUNE 2016 Syöpälääkkeiden kehitys on ollut hyvä, ja yhä useammat paranevat.

More information

THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 199 PATIENT GROUPS with an interest in RARE DISEASES

THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 199 PATIENT GROUPS with an interest in RARE DISEASES THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 199 PATIENT GROUPS with an interest in RARE DISEASES PUBLISHED MAY 2016 Dans notre domaine de maladies rares où des efforts ont été faits pour

More information

Corporate Reputation of Pharma in 2017 the Patient Perspective

Corporate Reputation of Pharma in 2017 the Patient Perspective PRESS RELEASE: 'Corporate Reputation of Pharma in - the Global Patient Perspective' Corporate Reputation of Pharma in the Patient Perspective EMBARGOED PRESS RELEASE: 6AM GMT, THURSDAY, APRIL 5TH 2018

More information

Table of contents. Executive Summary. Chapter 1 Introduction. Chapter 2 Trends in monoclonal antibody dealmaking

Table of contents. Executive Summary. Chapter 1 Introduction. Chapter 2 Trends in monoclonal antibody dealmaking Table of contents Executive Summary Chapter 1 Introduction Chapter 2 Trends in monoclonal antibody dealmaking 2.1. Introduction 2.2. Monoclonal antibody partnering over the years 2.3. Bigpharma monoclonal

More information

BIOPHARMACEUTICALS A GLOBAL MARKET OVERVIEW

BIOPHARMACEUTICALS A GLOBAL MARKET OVERVIEW BIOPHARMACEUTICALS A GLOBAL MARKET OVERVIEW The study reviews, analyzes and projects the global market for Biopharmaceuticals for the period 2006 2015 PUBLISHED: APRIL 2010 Report Code: BT001 Pages: 240

More information

THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 118 PATIENT GROUPS with an interest in RESPIRATORY CONDTIONS

THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 118 PATIENT GROUPS with an interest in RESPIRATORY CONDTIONS THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 118 PATIENT GROUPS with an interest in RESPIRATORY CONDTIONS PUBLISHED OCTOBER 2016 [Question to respondents: Which companies have the best record

More information

Forest Laboratories, Inc. Bristol-Myers Squibb Company

Forest Laboratories, Inc. Bristol-Myers Squibb Company P Number P1001 P1002 P1003 P1009 P1014 P1149 P1004 P1176 P1005 P1006 P1057 P1007 P1008 P1010 P1011 P1012 P1013 P1082 P1128 P1015 P1125 P1170 P1017 P1018 P1019 P1022 P1023 P1024 Manufacturer Name Forest

More information

Asia Pac Compliance Code and APEC Principles and Nanjing Declaration Updates - Healthier China Through Innovation

Asia Pac Compliance Code and APEC Principles and Nanjing Declaration Updates - Healthier China Through Innovation Asia Pac Compliance Code and APEC Principles and Nanjing Declaration Updates - Healthier China Through Innovation Henry Li, General Counsel, RDPAC Beijing, China About RDPAC: R&D based Pharmaceutical Association

More information

USP Packing General Chapters <661.1>, <381>, <665>: An Industry Perspective on Elemental Impurities Compliance for Container/Closure

USP Packing General Chapters <661.1>, <381>, <665>: An Industry Perspective on Elemental Impurities Compliance for Container/Closure USP Packing General Chapters , , : An Industry Perspective on Elemental Impurities Compliance for Container/Closure Tim Shelbourn Co-chair, IQ Consortium ICH Q3D Compliance Working Group

More information

Generic Series: Optimizing Brand Lifecycle Management

Generic Series: Optimizing Brand Lifecycle Management A Datamonitor report Generic Series: Optimizing Brand Lifecycle Management Winning Strategies to Maximize Revenue in the Face of Growing Generic Competition Published: Jun-08 Product Code: Providing you

More information

Dir Analytical Dev. Sr Stability & Regulatory Scientist. Quality Control Sr Mgr. Principal Scientist

Dir Analytical Dev. Sr Stability & Regulatory Scientist. Quality Control Sr Mgr. Principal Scientist TITLE COMPANY Dir Analytical Dev Patheon Assoc Dir Quality Control Boehringer Ingelheim Sr Stability & Regulatory Scientist GlaxoSmithKline Quality Control Sr Mgr Sr Analytical Chemist Mallinckrodt Technical

More information

PASS-PAES-HTA studies

PASS-PAES-HTA studies PASS-PAES-HTA studies A view from academia Nicholas Moore University of Bordeaux Disclosure 2 Conflict of interest statement I & my department have worked or are working with, or have received various

More information

CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS

CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS CENTRAL NERVOUS SYSTEM (CNS) : TECHNOLOGIES AND GLOBAL MARKETS BIO074C March 2016 Jackson Highsmith Project Analyst ISBN: 1-62296-246-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215

More information

CAPDM Profile. The Canadian Association for Pharmacy Distribution Management. Representing Healthcare Distribution in Canada

CAPDM Profile. The Canadian Association for Pharmacy Distribution Management. Representing Healthcare Distribution in Canada CAPDM Profile The Canadian Association for Pharmacy Distribution Management Representing Healthcare Distribution in Canada CAPDM VISION Ensuring safe, secure, and timely access to high quality healthcare

More information

MEDIUS PARTNERING. July Global specialist provider of Business Development services to the Pharmaceutical and Healthcare Sectors

MEDIUS PARTNERING. July Global specialist provider of Business Development services to the Pharmaceutical and Healthcare Sectors MEDIUS PARTNERING July 2017 Global specialist provider of Business Development services to the Pharmaceutical and Healthcare Sectors Medius Associates Healthcare Business Development consultancy founded

More information

BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS

BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS : TECHNOLOGIES AND GLOBAL MARKETS BIO061C April 2014 Jackson Highsmith Project Analyst ISBN: 1-56965-801-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within

More information

Product Overview: Global Life Sciences Survey. One Firm. Complete Solutions.

Product Overview: Global Life Sciences Survey. One Firm. Complete Solutions. Product Overview: Global Life Sciences Survey One Firm. Complete Solutions. Unmatched Life Sciences Expertise 59 Reporting Countries 812 Participating Organizations 1,900 Unique Jobs Surveyed 390 Thousand

More information

GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS

GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BIO021E May 2016 Shalini Shahani Dewan Project Analyst ISBN: 1-62296-288-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA

More information

Pharmaceutical Companies and Social Media: Developing New Strategies

Pharmaceutical Companies and Social Media: Developing New Strategies Pharmaceutical Companies and Social Media: Developing New Strategies Jena Cutie jena@saaraams.com Karthika Karindalam karthika@saaraams.com 1 2 3 Executive Summary Best Practices and Strategies Pharma

More information

Patients are Counting on Us: It s Time to Act

Patients are Counting on Us: It s Time to Act Patients are Counting on Us: It s Time to Act Brian Johnson Chairman Rx-360 Senior Director Supply Chain Security Pfizer, Inc. 24 th Global GS1 Healthcare Conference October 2, 2013 THE WALL STREET JOURNAL

More information

Datamonitor Healthcare Pharma intelligence informa Datamonitor Healthcare Content Calendar

Datamonitor Healthcare Pharma intelligence informa Datamonitor Healthcare Content Calendar Datamonitor Healthcare 2017 Datamonitor Healthcare Content Calendar 2017 Content Calendar Published February 2017 Datamonitor Healthcare provides up-to-date insights and analysis that you can trust. Disease

More information

by Dennis van Rooij and Tim van Tongeren

by Dennis van Rooij and Tim van Tongeren July 10, 2015 DISCIPLINE DRIVES DIGITAL EXCELLENCE IN PHARMA Digital Teams Are Change Agents As Much As They Are Capability Engineers by Dennis van Rooij and Tim van Tongeren EXECUTIVE SUMMARY A new wave

More information

Evaluate Data Kit Pharma, Biotech and Medtech, May 2018

Evaluate Data Kit Pharma, Biotech and Medtech, May 2018 Evaluate Data Kit Pharma, Biotech and Medtech, May 2018 Contents Introduction 2 Sourcing Instructions / About Evaluate 3 Section 1 Pharma Industry Overview Top 15 Rx and OTC Sales 4 WW Rx and OTC Sales

More information

Theme Sub-theme Quote / issue. Inconsistency and

Theme Sub-theme Quote / issue. Inconsistency and Theme Sub-theme Quote / issue Inconsistency and ambiguity Problematic and contradictory use of the term "all". Abbvie's webpage describing their transparency policy says "AbbVie will submit a manuscript

More information

Immunotoxicology Technical Committee (ITC) HESI Assembly of Members January 19, 2009

Immunotoxicology Technical Committee (ITC) HESI Assembly of Members January 19, 2009 Immunotoxicology Technical Committee (ITC) HESI Assembly of Members January 19, 2009 Committee Leadership Dr. Ellen Evans (Schering-Plough Research Institute), Chair Dr. Tom Kawabata (Pfizer Inc.), Vice

More information

Disclosures and Acknowledgments

Disclosures and Acknowledgments 214 Cooperative Meeting of the Consortium of Multiple Sclerosis Centers and Americas Committee for Treatment and Research in Multiple Sclerosis Dallas, Texas DX1 Disability Progression in Multiple Sclerosis

More information

INVEST IN PROFIT PERFORMANCE STABILITY ERFORMANCE INNOVATION DIVER IVERSITY STABILITY PROFIT PERF INNOVATION PROFIT DIVERSITY ST

INVEST IN PROFIT PERFORMANCE STABILITY ERFORMANCE INNOVATION DIVER IVERSITY STABILITY PROFIT PERF INNOVATION PROFIT DIVERSITY ST PROFIT PERFORMANCE STABILITY ERFORMANCE INNOVATION DIVER INVEST IN DIVERSITY STABILITY PROFIT PERF NNOVATION PROFIT DIVERSITY STA STABILITY DIVERSITY INNOVATION CANADA S COMPETITIVE ADVANTAGES IVERSITY

More information

provides the most effective method of ensuring product security

provides the most effective method of ensuring product security 28 Buenos Aires ETIF 2010 - International and ANVISA Traceability Requirements G. Rossi 2010 rev. 1.0 Supports anti-counterfeiting and public health Combats fraud and prevents reimbursement fraud Reduces

More information

March 17, 2018 Ranking the Experience of European Physicians Interactions With Pharma. by Tim van Tongeren with Dennis van Rooij and Carlos Capella

March 17, 2018 Ranking the Experience of European Physicians Interactions With Pharma. by Tim van Tongeren with Dennis van Rooij and Carlos Capella March 17, 2018 Ranking the Experience of European Physicians Interactions With Pharma by Tim van Tongeren with Dennis van Rooij and Carlos Capella Executive Summary Each year, the pharmaceutical industry

More information

GLOBAL MARKETS FOR DRUG REPURPOSING

GLOBAL MARKETS FOR DRUG REPURPOSING GLOBAL MARKETS FOR DRUG REPURPOSING PHM175A January 2016 Shalini Shahani Dewan Project Analyst ISBN: 1-62296-202-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free

More information

[ BIOPHARMACEUTICALS ] [ BIOPHARMACEUTICALS ] Canada s competitive advantages

[ BIOPHARMACEUTICALS ] [ BIOPHARMACEUTICALS ] Canada s competitive advantages [ BIOPHARMACEUTICALS ] [ BIOPHARMACEUTICALS ] Canada s competitive advantages CANADA S PHARMACEUTICAL SECTOR Canada offers a dynamic and innovative environment for pharmaceutical companies, with first-rate

More information

INVESTOR PRESENTATION 2018

INVESTOR PRESENTATION 2018 INVESTOR PRESENTATION 2018 IMMUNOPRECISE ANTIBODIES, LTD. UNIT 3204-4464 MARKHAM STREET VICTORIA, BRITISH COLUMBIA V8Z 7X8, CANADA IMMUNOPRECISE.COM 1 Disclosures DISCLAIMER This presentation is not, and

More information

France Pharma RepTrak 2017

France Pharma RepTrak 2017 France Pharma RepTrak 2017 The World s Most Reputable Pharmaceutical Companies in France Olivier Forlini, Director Reputation Institute France June 2017 1 Why Measure Reputation? The success of your company

More information

IMPROVING TALENT ACQUISITON OUTCOMES

IMPROVING TALENT ACQUISITON OUTCOMES IMPROVING TALENT ACQUISITON OUTCOMES Harry Griendling Founder & CEO March, 2017 2017 DoubleStar, Inc. Proprietary work product. Reproduction or external distribution without prior permission is strictly

More information

THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (SPANISH EDITION)

THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (SPANISH EDITION) THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (SPANISH EDITION) Feedback from 108 Spanish patient groups PUBLISHED MAY 2016 Nuevos tratamientos con precios que impidan el acceso para

More information

Strategic vision of Pharma Market

Strategic vision of Pharma Market Strategic vision of Pharma Market Evolution 2012-2016 ACIP Presentation, Paris January 30, 2013 Introduction This presentation draws strategic orientations for pharma companies considering the expected

More information

Market Access. Summit. 17 th Annual. Media Kit and Sponsorship Packages. November 12th & 13th, 2018 Toronto, ON

Market Access. Summit. 17 th Annual. Media Kit and Sponsorship Packages.   November 12th & 13th, 2018 Toronto, ON 17 th Annual Market Access November 12th & 13th, 2018 Toronto, ON Media Kit and Sponsorship Packages www.marketaccesscanada.ca 17 th Annual Market Access 17th ANNUAL MARKET ACCESS SUMMIT MEDIAKIT November

More information

Global Oncology Biosimilars Market

Global Oncology Biosimilars Market Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Oncology Biosimilars Market 2016-2020 Global Oncology Biosimilars Market 2016-2020 Publication ID: TNV0216071

More information

Montagna Symposium on the Biology of Skin

Montagna Symposium on the Biology of Skin 2017 Sustaining Members Curtis T. Thompson, M.D. & LLC Novartis Pharmaceuticals Corporation Procter & Gamble Company Valeant Pharmaceuticals International, Inc. The Company of Biologists The David M.C.

More information

GLOBAL MARKETS FOR BIOENGINEERED PROTEIN DRUGS

GLOBAL MARKETS FOR BIOENGINEERED PROTEIN DRUGS GLOBAL MARKETS FOR BIOENGINEERED PROTEIN DRUGS BIO009G January 2017 Shalini Shahani Dewan Project Analyst ISBN: 1-62296-417-9 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215

More information

2011 Participating Manufacturer Labeler Codes

2011 Participating Manufacturer Labeler Codes Acton Pharmaceu.cals, Inc. 1/1/11 1/1/11 Incyte Corpora.on 1/1/11 1/1/11 Rosemont Pharmaceu.cals Limited 1/1/11 1/1/11 Solvay Biologicals 1/1/11 1/1/11 00002 Eli Lilly and Company 1/1/11 1/1/11 00003 E

More information

Business Development & Licensing Journal

Business Development & Licensing Journal www.plgeurope.com Business Development & Licensing Journal For the Pharmaceutical Licensing Groups Strategic options for getting the most out of late-stage licensing deals Trends in the therapeutic area

More information

PROGRAM AGENDA- AS OF JULY 28, 2008

PROGRAM AGENDA- AS OF JULY 28, 2008 PROGRAM AGENDA- AS OF JULY 28, 2008 PLEASE NOTE THAT THIS CONFERENCE AGENDA IS SUBJECT TO CHANGE AS WE CONTINUALLY WORK TOWARDS BRINGING YOU THE BEST POSSIBLE TOPICS AND SPEAKERS. SUNDAY NOVEMBER 9, 2008

More information

Regulatory Information Management

Regulatory Information Management Regulatory Information Management Hotel Meliá Avenida América, Madrid http://www.reginfomanagement.com/ Day 1 - Tuesday 26 April 2016 08:30-09:00 Conference Registration 09:00-09:10 Opening remarks from

More information

THE STATE OF DIGITAL EXCELLENCE IN THE PHARMACEUTICAL INDUSTRY, 2015: CAPABILITIES

THE STATE OF DIGITAL EXCELLENCE IN THE PHARMACEUTICAL INDUSTRY, 2015: CAPABILITIES April 2, 2015 THE STATE OF DIGITAL EXCELLENCE IN THE PHARMACEUTICAL INDUSTRY, 2015: CAPABILITIES Firms Require a More Disciplined Approach to Improving Digital Maturity by Tim van Tongeren and Dennis van

More information

Current Status of Pharmaceutical Patenting at United States Patent Office Rau. B. S Appaji P. V

Current Status of Pharmaceutical Patenting at United States Patent Office Rau. B. S Appaji P. V Current Status of Pharmaceutical Patenting at United States Patent Office Rau. B. S Appaji P. V Abstract: Indian pharmaceutical industry has proved manufacture of global quality pharmaceutical products

More information

Clinical Trials Insight. World Pharmaceutical Frontiers

Clinical Trials Insight. World Pharmaceutical Frontiers ABOUT CLINICAL TRIALS INSIGHT The cost of bringing a new drug to market is staggering. Major pharmaceutical companies now invest between $4 billion and $12 billion in developing each new product. Containing

More information

The Novasecta European MidPharma Report 2016

The Novasecta European MidPharma Report 2016 The Novasecta European MidPharma Report 2016 Working closely with such companies for over a decade has provided us with a unique perspective and a substantial body of practical insight into how pharmaceutical

More information

Parameters of Development - Drug Delivery Enabled/Enhanced Products (DDEP ) A Review (Chapter 7)

Parameters of Development - Drug Delivery Enabled/Enhanced Products (DDEP ) A Review (Chapter 7) CHAPTER 7 FDA DRUG APPROVALS, 2000-2010 Introduction This chapter reviews drug delivery enabled/enhanced product approvals by the FDA over the period 2000-2010. This is a simple analysis that provides

More information

NEXT Annual Report 2017

NEXT Annual Report 2017 NEXT Annual Report 2017 June 2018 Final version NEXT Annual Report 2017 Executive Summary The number of early clinical trials carried out in the centers exceeded the number anticipated in the original

More information

New medicines for better health.

New medicines for better health. New medicines for better health. Message from the Chairman of the European Federation of Pharmaceutical Industries and Associations, Japan (EFPIA Japan) EFPIA Japan was established in 2002, and represents

More information

Realizing the National Health IT Strategy Through the Adoption of a Standardized Digital Identity Solution

Realizing the National Health IT Strategy Through the Adoption of a Standardized Digital Identity Solution Realizing the National Health IT Strategy Through the Adoption of a Standardized Digital Identity Solution Mollie Shields-Uehling SAFE-BioPharma Association SAFE-BioPharma Association Agenda Why do we

More information

New medicines for better health.

New medicines for better health. New medicines for better health. Message from the Chairman of the European Federation of Pharmaceutical Industries and Associations, Japan (EFPIA Japan) EFPIA Japan was established in 2002, and represents

More information

Teriflunomide Efficacy and Safety in Pa8ents with Relapsing Mul8ple Sclerosis: Results from TOWER, a Second Pivotal Phase 3 Placebo- Controlled Study

Teriflunomide Efficacy and Safety in Pa8ents with Relapsing Mul8ple Sclerosis: Results from TOWER, a Second Pivotal Phase 3 Placebo- Controlled Study Efficacy and Safety in Pa8ents with Relapsing Mul8ple Sclerosis: Results from, a Second Pivotal Phase 3 - Controlled Study Aaron E. Miller; 1 Ludwig Kappos; 2 Giancarlo Comi; 3 Chris>an Confavreux; 4 Mark

More information

Sample Attending Companies and Job Titles as of 5 November Attending Companies

Sample Attending Companies and Job Titles as of 5 November Attending Companies Sample Attending Companies and Job Titles as of 5 November 2018 Ajinomoto Co Inc Almac Group Ltd Alnylam Pharmaceuticals Inc Ambiopharm Ardena ChemConnection B V ART BioScience Ascendis Pharma GmbH Aspen

More information

Reporting Gifts to Physicians A Few Dark Clouds Obscure the Sunshine By John Mack

Reporting Gifts to Physicians A Few Dark Clouds Obscure the Sunshine By John Mack www.pharmamarketingnews.com April 2008 Vol. 7, No. 4 Published by VirSci Corp. www.virsci.com Article Reporting Gifts to Physicians A Few Dark Clouds Obscure the Sunshine By John Mack PMN74-04 Submit comments

More information

Global and China Biopharmaceutical Industry Report, 2010

Global and China Biopharmaceutical Industry Report, 2010 Global and China Biopharmaceutical Industry Report, 2010 In recent years, biopharmaceutical industry has been the fastest growing sector in the global pharmaceutical industry. From 1998 to 2009, the compound

More information

Helping Pharmas Manage Compliance Risks for Speaker Programs

Helping Pharmas Manage Compliance Risks for Speaker Programs COGNIZANT 20-20 Helping Pharmas Manage Compliance Risks for Speaker Programs By taking a rigorous and thoughtful approach that pivots around key performance indicators, pharmaceuticals companies can proactively

More information

The SAFE Standard: Digital Signatures for Achieving Global, Compliant Requirements for Health Care

The SAFE Standard: Digital Signatures for Achieving Global, Compliant Requirements for Health Care The SAFE Standard: Digital Signatures for Achieving Global, Compliant Requirements for Health Care Terry Zagar Core Team Member SAFE-BioPharma Association SAFE-BioPharma Association The Business Case For

More information

Invest in Canada BIOPHARMACEUTICALS. Canada s competitive advantages

Invest in Canada BIOPHARMACEUTICALS. Canada s competitive advantages 211 Invest in Canada BIOPHARMACEUTICALS Canada s competitive advantages MAJOR GLOBAL INVESTORS IN canada Amgen AstraZeneca Bayer Bristol-Myers Squibb GlaxoSmithKline Johnson & Johnson Jubilant Life Sciences

More information

Innovation for Pharma to engage with the mobile user.

Innovation for Pharma to engage with the mobile user. www.healthnetworkcommunications.com/mobile Innovation for Pharma to engage with the mobile user 24-27 April 2012 Sheraton Hotel, Amsterdam, The Netherlands created by sponsor endorsed by Smart phones and

More information

Sponsorship & Branding opportunities

Sponsorship & Branding opportunities Learn. Connect. Optimize. Tuesday, June 26, 2018 Hyatt regency Hotel, New Brunswick, New Jersey education Forums networking keynote speaker Sponsorship & Branding opportunities Limited Sponsorships available!

More information

Industry Biomanufacturing Capacity Overview Patti Seymour Senior Consultant BioProcess Technology Consultants, Inc. DCAT March 14 17, 2016

Industry Biomanufacturing Capacity Overview Patti Seymour Senior Consultant BioProcess Technology Consultants, Inc. DCAT March 14 17, 2016 Global Biomanufacturing Trends, Capacity and Technology Drivers Industry Biomanufacturing Capacity Overview Patti Seymour Senior Consultant BioProcess Technology Consultants, Inc. DCAT March 14 17, 2016

More information

An Industry Perspective: The Complexity of Postapproval CMC Changes and Proposed Regulatory Strategies. SPEAKER: Suzanne Murray Biogen

An Industry Perspective: The Complexity of Postapproval CMC Changes and Proposed Regulatory Strategies. SPEAKER: Suzanne Murray Biogen An Industry Perspective: The Complexity of Postapproval CMC Changes and Proposed Regulatory Strategies SPEAKER: Suzanne Murray Biogen Contents 1. BioPhorum Operations Group (BPOG) and the Post-approvals

More information

GLOBAL PHARMA INDUSTRY

GLOBAL PHARMA INDUSTRY www. Advancing Development & Manufacturing CONNECTING THE GLOBAL PHARMA INDUSTRY SINCE 1977 2015 M E D I A PLANNER BRANDING Advancing Development & Manufacturing Pharmaceutical Technology Expert Insight.

More information

A2 Micro: Business Objec2ves

A2 Micro: Business Objec2ves A2 Micro: Business Objec2ves A short revision webinar covering profit maximisa5on, changes in costs and revenues and pricing with different business objec5ves Revising A2 Economics (Micro) Build lots of

More information

LSE Health Market Access Academy April 2018, London September 2018, London

LSE Health Market Access Academy April 2018, London September 2018, London LSE Health Market Access Academy 9 13 April 2018, London 10 14 September 2018, London In cooperation with the Boston Consulting Group Market Access Roundtable LSE Health Market Access Academy 2 The London

More information

Twenty Years of TRIPS Agreement: What Difference Did Product Patent Protection Make to the Pharmaceutical Industry in India?

Twenty Years of TRIPS Agreement: What Difference Did Product Patent Protection Make to the Pharmaceutical Industry in India? Twenty Years of TRIPS Agreement: What Difference Did Product Patent Protection Make to the Pharmaceutical Industry in India? Sudip Chaudhuri Indian Institute of Management Calcutta International Workshop

More information

on the Joyce Chehade, formerly Senior Brand Manager at Pendopharm Inc., has been appointed Senior Product Manager, Gastroenterology, at Ferring Inc.

on the Joyce Chehade, formerly Senior Brand Manager at Pendopharm Inc., has been appointed Senior Product Manager, Gastroenterology, at Ferring Inc. PEOPLE on the Copyright MOVE Not for Sale or Commercial Distribution Unauthorised use prohibited. Authorised users can download, display, view and print a single copy for personal use PHARMA COMPANIES

More information

CDISC ST R MEMBERSHIP April 2018

CDISC ST R MEMBERSHIP April 2018 Amgen Boehringer Ingelheim Pharmaceuticals Bristol Myers Squibb Certara CompleWare Corporation Duke Clinical Research Institute Eli Lilly and Company GlaxoSmithKline IQVIA Johnson & Johnson Merck & Co.,

More information

Personalized healthcare Getting from promise to reality

Personalized healthcare Getting from promise to reality Personalized healthcare Getting from promise to reality Severin Schwan, CEO Roche Group Swiss-American Chamber of Commerce, 26 August 2009 1 Roche The challenge Personalised healhcare Implementation at

More information

Montagna Symposium on the Biology of Skin

Montagna Symposium on the Biology of Skin 2016 Sustaining Members Anacor Pharmaceuticals, Inc. Galderma International Amgen USA Curtis T. Thompson, M.D. & LLC The David M.C. Ju Foundation Johnson & Johnson Consumer Inc. Tioga Pharmaceuticals,

More information

May Marketing ROI INSIDE. Facing pharma s big challenges. A call for innovation. Creating brand advocates. in partnership with

May Marketing ROI INSIDE. Facing pharma s big challenges. A call for innovation. Creating brand advocates. in partnership with May 2007 Marketing ROI INSIDE Facing pharma s big challenges A call for innovation Creating brand advocates in partnership with C O N T E N T S May 2007 Marketing ROI INSIDE Facing pharma s big challenges

More information

2007 M E DIA PLAN N E R

2007 M E DIA PLAN N E R 2007 MEDIA PLANNER The Content OUR MISSION For more than 35 years, Pharmaceutical Representative has been the industry s leading source of ongoing sales insight and development. It provides the essential

More information

VALUE IN HEALTH 14 (2011) A215 A222 ISPOR 16TH ANNUAL INTERNATIONAL MEETING FINANCIAL DISCLOSURE INFORMATION FOR RESEARCH PRESENTATIONS

VALUE IN HEALTH 14 (2011) A215 A222 ISPOR 16TH ANNUAL INTERNATIONAL MEETING FINANCIAL DISCLOSURE INFORMATION FOR RESEARCH PRESENTATIONS VALUE IN HEALTH 14 (2011) A215 A222 A215 ISPOR 16TH ANNUAL INTERNATIONAL MEETING FINANCIAL DISCLOSURE INFORMATION FOR RESEARCH PRESENTATIONS The International Society for Pharmacoeconomics and Outcomes

More information

Extended Producer Responsibility: California and Beyond

Extended Producer Responsibility: California and Beyond Extended Producer Responsibility: California and Beyond Western Sustainability Pollution Prevention Network Oct 29, 2009 By: Heidi Sanborn, Executive Director This Presentation Covers Why EPR For Pollution

More information

Welcome to the CMC Strategy Forum Europe 2016

Welcome to the CMC Strategy Forum Europe 2016 Welcome to the CMC Strategy Forum Europe 2016 The 10 th annual CMC Strategy Forum Europe, organized by CASSS, will explore a number of critical topics focused on improving the quality in development and

More information

Montagna Symposium on the Biology of Skin

Montagna Symposium on the Biology of Skin 2014 Sustaining Members The Estée Lauder Companies, Inc. Galderma International Advancing Innovation in Dermatology, Inc. DUSA Pharmaceuticals, Inc. Johnson & Johnson Consumer & Personal Products Worldwide

More information

Clinical Trials Insight. World Pharmaceutical Frontiers

Clinical Trials Insight. World Pharmaceutical Frontiers About Clinical trials insight The cost of bringing a new drug to market is staggering. Major pharmaceutical companies now invest between $4 billion and $12 billion in developing each new product. Containing

More information

Welcome! Duchenne Muscular Dystrophy Regulatory Science Consor6um (D-RSC)

Welcome! Duchenne Muscular Dystrophy Regulatory Science Consor6um (D-RSC) Welcome! Duchenne Muscular Dystrophy Regulatory Science Consor6um (D-RSC) June 23, 2016 1 D-RSC Team Jane Larkindale, Execu:ve Director Pat Furlong, PPMD Co-Director Charles Lynn, Sr. Project Manager Klaus

More information

Welcome to. January 26, The Mayflower Hotel Washington, DC USA

Welcome to. January 26, The Mayflower Hotel Washington, DC USA Welcome to January 26, 2015 The Mayflower Hotel Washington, DC USA Mission Statement Provide a venue for biotechnology/biological product discussion that focuses on relevant CMC issues throughout the lifecycle

More information

Workshop on Cytokine Release: State-of-the-Science, Current Challenges and Future Directions

Workshop on Cytokine Release: State-of-the-Science, Current Challenges and Future Directions Workshop on Cytokine Release: State-of-the-Science, Current Challenges and Future Directions Sponsored by the HESI Immunotoxicology Technical Committee Silver Spring, MD 22 October 2013 Objectives of the

More information

1 st BME GLOBAL PHARMA SUPPLY CHAIN CONGRESS 2016

1 st BME GLOBAL PHARMA SUPPLY CHAIN CONGRESS 2016 1 st BME GLOBAL PHARMA SUPPLY CHAIN CONGRESS 2016 Innovative patient-centric Supply Chain models to improve access to medicines worldwide February 22 nd - 25 th 2016 Marriot Hotel Frankfurt Germany WHY

More information

Public private partnerships to encourage patient access

Public private partnerships to encourage patient access Public private partnerships to encourage patient access 5 th SFE SFUS Conference Challenges for efficient health care in Central and Eastern Europe Belgrade, 10 th October 2015 How does IMI work? The Innovative

More information

SafeSciMET. European Modular Education and Training Programme in Safety Sciences for Medicines

SafeSciMET. European Modular Education and Training Programme in Safety Sciences for Medicines SafeSciMET European Modular Education and Training Programme in Safety Sciences for Medicines What patients need What Europe needs Rapid exploitation of insights in disease mechanisms for introduction

More information

6/20/2016 BIOSIMILARS: US OVERVIEW JUNE 9, Shawn Brown, VP International Affairs Allergan Inc. DISCUSSION TOPICS

6/20/2016 BIOSIMILARS: US OVERVIEW JUNE 9, Shawn Brown, VP International Affairs Allergan Inc. DISCUSSION TOPICS BIOSIMILARS: US OVERVIEW JUNE 9, 2016 Shawn Brown, VP International Affairs Allergan Inc. DISCUSSION TOPICS Current Market BSUFA Negotiations Medicare Part D + CMS Reimbursement Legal Questions (Amgen

More information

Conflict of Interest Disclosure

Conflict of Interest Disclosure Brian L. Strom, M.D., M.P.H. Chair and Professor, Department of Biostatistics and Epidemiology Director, Center for Clinical Epidemiology and Biostatistics George S. Pepper Professor of Public Health and

More information

Genetic Toxicology Technical Committee (GTTC)

Genetic Toxicology Technical Committee (GTTC) Genetic Toxicology Technical Committee (GTTC) Stefan Pfuhler Procter and Gamble Co. Committee Co-Chair HESI Annual Meeting June 10, 2014 GTTC s Past and Present Areas of Focus and Impact Improve the scientific

More information

The 2016 Avoca Report

The 2016 Avoca Report The 2016 Avoca Report Strategic Partnerships Under Scrutiny: A Renewed Look at the State of Clinical Outsourcing SPONSOR & PROVIDER PERCEPTIONS October 2016 Introduction Each year, The Avoca Group surveys

More information

Coordination and Support Action: Enabling platform on medicines adaptive pathways to patients

Coordination and Support Action: Enabling platform on medicines adaptive pathways to patients Coordination and Support Action: Enabling platform on medicines adaptive pathways to patients Solange Rohou (AZ) & Luk Maes (BMS) 17.12.2014 IMI webinar Content Background information CSA project proposal

More information

THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (GERMAN EDITION)

THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (GERMAN EDITION) THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (GERMAN EDITION) Feedback from 60 German patient groups PUBLISHED JUNE 2016 Die neuen, extrem hohen Hepatitis-C- Medikamenten-Preise haben

More information

on the Canadian Pharmaceutical Marketing l February/March

on the Canadian Pharmaceutical Marketing l February/March PEOPLE on the MOVE PHARMA COMPANIES Mary Jo Climie has joined Biogen Idec Canada as Product Manager, Fampyra. Mary Jo comes to Biogen Idec from a successful sales and marketing career with Xerox, Merck

More information